









Markets
/
Stocks
/
nasdaq-xncr
/

Xencor Inc

XNCR



View Detailed Chart

15.450USD

-0.020-0.13%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

1.10BMarket Cap

LossP/E TTM



Xencor Inc

15.450

-0.020-0.13%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-0.13%

5 Days

-2.22%

1 Month

-7.71%

6 Months

+86.82%

Year to Date

-32.77%

1 Year

-36.39%

View Detailed Chart

TradingKey Stock Score of Xencor Inc

Currency: USD Updated: 2025-12-24

Key Insights

Xencor Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 52/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Xencor Inc's Score

Industry at a Glance

Industry Ranking

52 / 404

Overall Ranking

135 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 14 analysts

Buy

Current Rating

28.000

Target Price

+58.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Xencor Inc Highlights

StrengthsRisks

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 110.49M.

Fairly Valued

The company’s latest PE is -8.96, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.43M shares, decreasing 6.98% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 192.79K shares of this stock.